Figg, William D.

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab -Paclitaxel

Gardner, E. R., Dahut, W. L., Scripture, C. D., Jones, J., Aragon-Ching, J. B., Desai, N., Hawkins, M. J., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research

Cancer Treatment and PharmacologyNanoparticle-Based Drug Delivery

Cited by 226

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., Pomerantz, M., Freedman, M., Ross, R., Regan, M., et al. (2011) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPharmacogenetics and Drug Metabolism

Cited by 159

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology

Viral-associated cancers and disordersLymphoma Diagnosis and Treatment

Cited by 138

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Kummar, S., Raffeld, M., Juwara, L., Horneffer, Y., Strassberger, A., Allen, D., Steinberg, S. M., Rapisarda, A., Spencer, S. D., Figg, W. D., et al. (2011) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 115

Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers

Pluta, R. M., Oldfield, E. H., Bakhtian, K. D., Fathi, A. R., Smith, R. K., DeVroom, H. L., Nahavandi, M., Woo, S., Figg, W. D., & Lonser, R. R. (2011) · PLoS ONE

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 112

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

Walsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J., Jarosinski, P., Gupta, R., & Pizzo, P. A. (1997) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 109

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., et al. (2017) · Clinical Cancer Research

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 56

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 56

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramaswami, R., Lurain, K., Peer, C. J., Serquiña, A., Wang, V., Widell, A., Goncalves, P., Steinberg, S. M., Marshall, V., George, J., et al. (2020) · Blood

Viral-associated cancers and disordersCytomegalovirus and herpesvirus research

Cited by 51

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

Kazandjian, D., Hill, E., Dew, A., Morrison, C., Roswarski, J., Korde, N., Emanuel, M., Petrosyan, A., Bhutani, M., Calvo, K. R., et al. (2021) · JAMA Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 49

Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy

Hicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 44

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 24

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer

Figg, W. D. (1994) · Archives of Internal Medicine

Thyroid Disorders and TreatmentsPituitary Gland Disorders and Treatments

Cited by 10

Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial

Abel, M. L., Takahashi, N., Desai, P., Peer, C., Redon, C., Nichols, S., Vilimas, R., Lee, M.-J., Lee, S., Sciuto, L., et al. (2023) · Cancer Research

Cancer therapeutics and mechanismsPARP inhibition in cancer therapy

Cited by 4